$NDRA ENDRA Life Sciences Initiates Review of Strategic Alternatives to Maximize Shareholder Value
https://www.businesswire.com/news/home/202603...lder-Value
Board to evaluate a range of alternatives while continuing to support core business priorities
ANN ARBOR, Mich.--(BUSINESS WIRE)--ENDRA Life Sciences Inc. (Nasdaq: NDRA) (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today announced that its Board of Directors has initiated a process to evaluate a range of strategic alternatives aimed at maximizing shareholder value.
As a part of this process, the Board will evaluate a range of potential alternatives, including, but not limited to strategic investments, mergers, business combinations, in-licensing or collaboration arrangements, asset sales, or sale or merger of the Company.
ENDRA has engaged Lucid Capital Management as its financial advisor and K&L Gates as its legal counsel in connection with this process.
“The Board and management are committed to identifying and evaluating opportunities that may maximize the shareholder value while building on the progress we’ve made advancing ENDRA’s strategic priorities,” said Alexander Tokman, Chief Executive Officer of ENDRA Life Sciences. “We believe this process will help us assess a range of options available to the Company and determine the most appropriate path forward for ENDRA and its shareholders.”
The Company will continue to execute on its strategic and operating initiatives during the review process. The Company has not set a timetable for completion of the process, and does not intend to comment further unless and until additional disclosure is appropriate or required by law.
https://www.businesswire.com/news/home/202603...lder-Value
Board to evaluate a range of alternatives while continuing to support core business priorities
ANN ARBOR, Mich.--(BUSINESS WIRE)--ENDRA Life Sciences Inc. (Nasdaq: NDRA) (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today announced that its Board of Directors has initiated a process to evaluate a range of strategic alternatives aimed at maximizing shareholder value.
As a part of this process, the Board will evaluate a range of potential alternatives, including, but not limited to strategic investments, mergers, business combinations, in-licensing or collaboration arrangements, asset sales, or sale or merger of the Company.
ENDRA has engaged Lucid Capital Management as its financial advisor and K&L Gates as its legal counsel in connection with this process.
“The Board and management are committed to identifying and evaluating opportunities that may maximize the shareholder value while building on the progress we’ve made advancing ENDRA’s strategic priorities,” said Alexander Tokman, Chief Executive Officer of ENDRA Life Sciences. “We believe this process will help us assess a range of options available to the Company and determine the most appropriate path forward for ENDRA and its shareholders.”
The Company will continue to execute on its strategic and operating initiatives during the review process. The Company has not set a timetable for completion of the process, and does not intend to comment further unless and until additional disclosure is appropriate or required by law.
